The burden of neovascular age-related macular degeneration: a patient’s perspective

References

• WangJJForanSMitchellPAge-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye StudyClin Exp Ophthalmol2000284268273 Available from: http://onlinelibrary.wiley.com/doiAccessed November 26, 201811021555
   PubMed Web of Science ®Google Scholar
• KeelSXieJForemanJvan WijngaardenPTaylorHRDiraniMPrevalence of age-related macular degeneration in Australia: the Australian National Eye Health SurveyJAMA Ophthalmol2017135111242124929049463
   PubMed Web of Science ®Google Scholar
• FerrisFLFineSLHymanLAge-related macular degeneration and blindness due to neovascular maculopathyArch Ophthalmol198410211164016426208888
   PubMed Web of Science ®Google Scholar
• ArdenGBWolfJEColour vision testing as an aid to diagnosis and management of age related maculopathyBr J Ophthalmol20048891180118515317712
   PubMed Web of Science ®Google Scholar
• SlakterJSSturMQuality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatmentSurv Ophthalmol200550326327315850815
   PubMed Web of Science ®Google Scholar
• NollettCLBrayNBunceCHigh prevalence of untreated depression in patients accessing low-vision servicesOphthalmology2016123244044126278862
   PubMed Web of Science ®Google Scholar
• van der AaHPComijsHCPenninxBWvan RensGHvan NispenRMMajor depressive and anxiety disorders in visually impaired older adultsInvest Ophthalmol Vis Sci201556284985425604690
   PubMed Web of Science ®Google Scholar
• DawsonSRMallenCDGouldstoneMBYarhamRMansellGThe prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study dataBMC Ophthalmol2014147824923726
   PubMed Web of Science ®Google Scholar
• SenraHBalaskasKMahmoodiNAslamTExperience of Anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degenerationAm J Ophthalmol201717721322428302534
   PubMed Web of Science ®Google Scholar
• Hernandez TrilloADickinsonCMThe impact of visual and nonvisual factors on quality of life and adaptation in adults with visual impairmentInvest Ophthalmol Vis Sci20125374234424122599581
   PubMed Web of Science ®Google Scholar
• MantelINiderprimSAGianniouCDeliAAmbresinAReducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimenBr J Ophthalmol20149891192119624729031
   PubMed Web of Science ®Google Scholar
• EmersonMVLauerAKCurrent and emerging therapies for the treatment of age-related macular degenerationClin Ophthalmol200822377388 Available from: https://www.dovepress.com/getfile.php?fileID=2926Accessed November 26, 201819668729
   PubMedGoogle Scholar
• PutsMTTapscottBFitchMA systematic review of factors influencing older adults’ decision to accept or decline cancer treatmentCancer Treat Rev201541219721525579752
   PubMed Web of Science ®Google Scholar
• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• PezzulloLStreatfeildJSimkissPShickleDThe economic impact of sight loss and blindness in the UK adult populationBMC Health Serv Res20181816329382329
   PubMed Web of Science ®Google Scholar
• HanemotoTHikichiYKikuchiNKozawaTThe impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese settingPLoS One20171212e018903529220371
   PubMed Web of Science ®Google Scholar
• PrennerJLHalperinLSRycroftCHogueSWilliams LiuZSeibertRDisease burden in the treatment of age-related macular degeneration: findings from a time-and-motion studyAm J Ophthalmol2015160472573126142721
   PubMed Web of Science ®Google Scholar
• BandelloFAugustinASahelJAAssociation between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and ItalyDrugs Aging200825325526818331076
   PubMed Web of Science ®Google Scholar
• BuckleMLeeAMohamedQPrevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United KingdomEye201529340340825592123
   PubMed Web of Science ®Google Scholar
• MorVLaliberteLMorrisJNWiemannMThe Karnofsky Performance Status Scale. An examination of its reliability and validity in a research settingCancer1984539200220076704925
   PubMed Web of Science ®Google Scholar
• DolanPModeling valuations for EuroQol health statesMed Care19973511109511089366889
   PubMed Web of Science ®Google Scholar
• Ravens-SiebererUWilleNBadiaXFeasibility, reliability, and validity of the EQ-5D-Y: results from a multinational studyQual Life Res201019688789720401552
   PubMed Web of Science ®Google Scholar
• StelmackJAStelmackTRMassofRWMeasuring low-vision rehabilitation outcomes with the NEI VFQ-25Invest Ophthalmol Vis Sci20024392859286812202503
   PubMed Web of Science ®Google Scholar
• MangioneCMLeePPGutierrezPRDevelopment of the 25-item National Eye Institute Visual Function QuestionnaireArch Ophthalmol200111971050105811448327
   PubMed Web of Science ®Google Scholar
• EvansJRLawrensonJGAntioxidant vitamin and mineral supplements for slowing the progression of age-related macular degenerationCochrane Database Syst Rev201211Cd00025423152201
   PubMed Web of Science ®Google Scholar
• Average Weekly Earnings A. cat. no. 6302.0. 2017. Accessed 21 November 2017
   Google Scholar
• Welfare AIoHaAustralia’s Health2014Canberra2014
   Google Scholar
• Deloitte Access EconomicsEyes on the Future: A Clear Outlook on Age-Related Macular Degeneration. Report prepared for the Macular Degeneration Foundation102011 Available from: http://www.mdfoundation.com.au/LatestNews/MDFoundationDeloitteAccessEconomicsReport2011.pdfAccessed August 23, 2018
   Google Scholar
• ReinDBZhangPWirthKEThe economic burden of major adult visual disorders in the United StatesArch Ophthalmol2006124121754176017159036
   PubMedGoogle Scholar
• CruessAFGordonKDBellanLMitchellSPezzulloMLThe cost of vision loss in Canada. 2. ResultsCan J Ophthalmol201146431531821816249
   PubMed Web of Science ®Google Scholar
• BoyleJVukicevicMKoklanisKItsiopoulosCReesGExperiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degenerationPsychol Health Med201823212714028064517
   PubMed Web of Science ®Google Scholar
• HongTMitchellPBurlutskyGFongCSRochtchinaEWangJJVisual impairment and subsequent use of support services among older people: longitudinal findings from the Blue Mountains Eye StudyAm J Ophthalmol2013156239339923688709
   PubMed Web of Science ®Google Scholar
• GohilRCrosby-NwaobiRForbesABurtonBHykinPSivaprasadSCaregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degenerationPLoS One2015106e012936126056840
   PubMed Web of Science ®Google Scholar
• TreharneGJLyonsACKitasGDAdherence to medicationN Engl J Med20053531819721974
   Google Scholar
• DroegeKMMuetherPSHermannMMAdherence to ranibizumab treatment for neovascular age-related macular degeneration in real lifeGraefes Arch Clin Exp Ophthalmol201325151281128423086225
   PubMed Web of Science ®Google Scholar
• VazeAFraser-BellSGilliesMConsequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degenerationActa Ophthalmol2014928e697e69824750589
   PubMed Web of Science ®Google Scholar
• DoughertyBEBullimoreMAComparison of scoring approaches for the NEI VFQ-25 in low visionOptom Vis Sci201087854354820526224
   PubMed Web of Science ®Google Scholar